You just read:

Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

News provided by

Mirati Therapeutics, Inc.

Jan 15, 2019, 16:21 ET